WIM INVESTMENT MANAGEMENT Ltd Acquires 43,400 Shares of GRAIL, Inc. $GRAL

WIM INVESTMENT MANAGEMENT Ltd increased its holdings in GRAIL, Inc. (NASDAQ:GRAL) by 68.9% in the fourth quarter, HoldingsChannel reports. The firm owned 106,400 shares of the company’s stock after purchasing an additional 43,400 shares during the period. GRAIL accounts for approximately 2.4% of WIM INVESTMENT MANAGEMENT Ltd’s portfolio, making the stock its 11th biggest holding. WIM INVESTMENT MANAGEMENT Ltd’s holdings in GRAIL were worth $9,107,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Farallon Capital Management LLC raised its position in shares of GRAIL by 168.7% in the third quarter. Farallon Capital Management LLC now owns 1,349,000 shares of the company’s stock valued at $79,766,000 after purchasing an additional 847,000 shares during the period. Bank of America Corp DE boosted its holdings in GRAIL by 121.0% during the third quarter. Bank of America Corp DE now owns 335,365 shares of the company’s stock valued at $19,830,000 after acquiring an additional 183,611 shares during the period. Allianz Asset Management GmbH boosted its holdings in GRAIL by 145.9% during the third quarter. Allianz Asset Management GmbH now owns 294,835 shares of the company’s stock valued at $17,434,000 after acquiring an additional 174,959 shares during the period. Vanguard Group Inc. boosted its holdings in GRAIL by 9.0% during the fourth quarter. Vanguard Group Inc. now owns 1,980,783 shares of the company’s stock valued at $169,535,000 after acquiring an additional 163,790 shares during the period. Finally, Invesco Ltd. boosted its holdings in GRAIL by 259.1% during the second quarter. Invesco Ltd. now owns 218,671 shares of the company’s stock valued at $11,244,000 after acquiring an additional 157,780 shares during the period.

Insider Buying and Selling

In related news, President Joshua J. Ofman sold 61,665 shares of the stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $49.92, for a total value of $3,078,316.80. Following the completion of the transaction, the president owned 371,216 shares of the company’s stock, valued at $18,531,102.72. This represents a 14.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Robert P. Ragusa sold 123,502 shares of the stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $49.92, for a total transaction of $6,165,219.84. Following the completion of the transaction, the chief executive officer directly owned 518,582 shares of the company’s stock, valued at $25,887,613.44. This trade represents a 19.23% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 310,267 shares of company stock valued at $15,485,396 over the last quarter. Corporate insiders own 1.83% of the company’s stock.

GRAIL Stock Down 2.4%

NASDAQ:GRAL opened at $60.47 on Thursday. GRAIL, Inc. has a 12-month low of $29.95 and a 12-month high of $118.84. The firm has a market capitalization of $2.60 billion, a PE ratio of -5.83 and a beta of 3.03. The firm has a 50-day moving average price of $51.64 and a 200 day moving average price of $77.78.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.76) by $0.47. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. The firm had revenue of $40.79 million during the quarter, compared to analyst estimates of $39.16 million. On average, research analysts expect that GRAIL, Inc. will post -11.09 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on GRAL. Piper Sandler upped their price target on shares of GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a report on Wednesday, May 6th. Robert W. Baird set a $70.00 target price on shares of GRAIL in a research note on Wednesday, May 6th. Guggenheim reduced their target price on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, March 30th. TD Cowen increased their target price on shares of GRAIL from $65.00 to $69.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Finally, Mizuho began coverage on shares of GRAIL in a research note on Friday, April 10th. They issued a “neutral” rating and a $58.00 target price for the company. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, GRAIL presently has a consensus rating of “Hold” and a consensus target price of $67.88.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.